Effect of Concurrent Chemoradiotherapy Combined with Sugemalimab on Tumour Response and Prognosis of Patients with Advanced Lung Cancer
Objective:To investigate the effect of simultaneous radiotherapy and chemotherapy combined with sugolizumab on tumor control and prognosis of advanced lung cancer patients.Methods:Eighty-two patients with advanced lung cancer who attended our hospital from January 2022 to January 2023 were selected as the study subjects,and were divided into the control group and the experimental group,41 cases each,according to the random draw method.The control group was given conventional synchronous radiotherapy treatment(cisplatin+etoposide)regimen,and the experimental group was given suglizumab-assisted synchronous radiotherapy treatment regimen.After 6 weeks of treatment,the short-term efficacy of the two groups was observed using the solid tumor efficacy evaluation criteria and the functional status score,and the level of T-lymphocyte subpopulations was observed using flow cytometry,and the six-month survival rate of the two groups was compared using the Log Rank χ2 test.Results:After six weeks of treatment,the objective remission rate of the experimental group was 65.85%,which was significantly higher than that of the control group,which was 29.26%(P<0.05).And the disease control rate of the experimental group was 92.86%,which was slightly higher than the 75.60%of the control group(P>0.05).At the end of treatment,the rate of stable improvement in the quality of survival of patients in the experimental group was 87.81%,which was higher than that of 41.46%in the control group(P<0.05).After treatment,CD3+,CD4+,and CD4+/CD8+were higher in the experimental group than in the control group(P<0.05);CD8+levels were lower in the experimental group than in the control group(P<0.05).Within 6 months of follow-up,the disease and death rate of patients in the control group was 14.63%,and the disease and death rate of the experimental group was 4.88%,and the difference in the prognostic disease and death rate of patients in the two groups was statistically significant(χ2=4.203,P=0.040).Conclusion:Synchronous radiotherapy and chemotherapy combined with sugolizumab can improve the recent efficacy and prognosis of advanced non-small cell lung cancer,improve the immune status of the patients,and improve the quality of survival,which has a good clinical application value.
Concurrent chemoradiotherapySugemalimabNon-small cell lung cancerTumor control
NETL
NSTL
万方数据
